Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802705 | 0.99 | KMT2A (0.42) | KMT2AGAAITGB1ITGA4MAPT | |
| SCHEMBL6801508 | 0.93 | ECE1 (0.38) | KMT2AGAAITGB1ITGA4PKM | |
| SCHEMBL6808867 | 0.92 | KMT2A (0.43) | KMT2AITGB1ITGA4MAPTITGB2 | |
| SCHEMBL6807848 | 0.90 | TACR1 (0.40) | GAAITGB1ITGA4ITGB2ICAM1 | |
| SCHEMBL6808312 | 0.89 | HSD17B10 (0.42) | KMT2AGAAITGB1ITGA4ECE1 | |
| SCHEMBL6803160 | 0.89 | ITGB2 (0.48) | ITGB1ITGA4MAPK1ITGB2ICAM1 | |
| SCHEMBL6809212 | 0.88 | POLB (0.53) | KMT2AGAAECE1MEN1 | |
| SCHEMBL7538530 | 0.88 | ITGB2 (0.48) | KMT2AGAAITGB1ITGA4MAPT | |
| SCHEMBL6812559 | 0.88 | TACR2 (0.41) | KMT2AGAAITGB1ITGA4ITGB2 | |
| SCHEMBL6812112 | 0.88 | ITGB2 (0.47) | ITGB1ITGA4MAPK1ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | KMT2A 3270/4885GAA 2094/4885ITGB1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.